FOXO4-DRI
Low EvidenceA senolytic peptide designed to selectively clear senescent cells by disrupting FOXO4-p53 interaction.
What It Is
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. By blocking this interaction, p53 is released to trigger apoptosis selectively in senescent cells while sparing healthy cells. A landmark 2017 mouse study showed improved fitness, fur density, and kidney function in aged mice. It represents a targeted approach to cellular senescence. In 2026 rankings of evidence-based anti-aging peptides, FOXO4-DRI entered the top 10 for the first time, reflecting growing preclinical evidence for selective senescent cell clearance. The senolytic approach — removing damaged cells rather than repairing them — is gaining traction as a complementary strategy alongside mitochondrial peptides (SS-31) and metabolic regulators (MOTS-c). As of early 2026, researchers continue to work on optimizing FOXO4-DRI and related senolytic peptides. Cleara Biotech, the company formed to commercialize the original Baar et al. research, remains a going preclinical concern focused on the FOXO4-p53 interaction as a therapeutic target. Side-by-side comparisons from the original study showed FOXO4-DRI cleared 70% of senescent cells with zero platelet count reduction, while navitoclax at equivalent senolytic efficacy dropped platelet counts by 40–60% — highlighting the peptide's selectivity advantage over small-molecule senolytics. No human trials have been initiated as of May 2026. Expanded in vitro work in 2026 using human chondrocytes confirmed selective removal of senescent cells while preserving healthy cell populations, supporting the peptide's potential for osteoarthritis and other joint-related degenerative conditions.
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| In vitro (human chondrocytes) | FOXO4-DRI selective senescent cell removal | Selectively removed senescent cells from expanded human chondrocytes while preserving healthy cells — relevant to osteoarthritis research | Source |
Commonly Discussed Benefits
Safety & Cautions
- Only one major published animal study
- No human clinical trials
- Senolytic effects could theoretically impact healthy cells
- Manufacturing complexity raises quality concerns
- Not FDA-approved
Comparisons
See how FOXO4-DRI compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
Continue Your Research
Track your research notes and set reminders in the companion app.
Related Peptides
Epithalon
Low EvidenceA tetrapeptide studied for its potential to activate telomerase and influence biological aging markers.
MOTS-c
Low EvidenceA mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity.